10
Views
1
CrossRef citations to date
0
Altmetric
Review

Pharmacoeconomics of folic acid supplementation for cardiovascular disease prevention

&
Pages 159-167 | Published online: 09 Jan 2014
 

Abstract

Epidemiological evidence, linking moderate elevations in homocysteine to cardiovascular events, is compelling but inconclusive. Folic acid and vitamin B12 have been used to reduce homocysteine levels and treat hyperhomocysteinemia. The clinical benefits will be established over the next 5 years as data from randomized trials becomes available. In this paper, two cost-effectiveness analyses examining ‘treating all’ versus ‘screen and treat’ are reviewed. Some experts are endorsing screening high-risk patients for elevated homocysteine but most professional societies recommend waiting until more evidence is available from peer-reviewed publications of the results of clinical trials before endorsing population-wide screening or treatment.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.